Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma.

Murphy CC, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL.

J Gastrointest Surg. 2013 Aug;17(8):1359-69. doi: 10.1007/s11605-013-2223-4. Epub 2013 May 29.

2.

Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting.

Murphy CC, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG.

Dis Esophagus. 2013 Sep-Oct;26(7):708-15. doi: 10.1111/dote.12019. Epub 2013 Jan 25.

PMID:
23350713
3.

Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.

Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR.

World J Gastroenterol. 2013 Dec 28;19(48):9282-93. doi: 10.3748/wjg.v19.i48.9282.

4.

Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.

Sio TT, Wilson ZC, Stauder MC, Bhatia S, Martenson JA, Quevedo JF, Schomas DA, Miller RC.

Am J Clin Oncol. 2016 Oct;39(5):448-52. doi: 10.1097/COC.0000000000000089.

PMID:
24879469
5.

Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.

Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL.

Ann Surg Oncol. 2012 May;19(5):1678-84. doi: 10.1245/s10434-011-2078-4. Epub 2011 Nov 2.

PMID:
22045465
6.

Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.

Sepesi B, Schmidt HE, Lada M, Correa AM, Walsh GL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Ajani JA, Watson TJ, Swisher SG, Low DE, Hofstetter WL.

Ann Thorac Surg. 2016 Mar;101(3):1075-80; Discussion 1080-1. doi: 10.1016/j.athoracsur.2015.09.063. Epub 2015 Dec 8.

PMID:
26680311
7.

Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.

Gabriel E, Attwood K, Du W, Tuttle R, Alnaji RM, Nurkin S, Malhotra U, Hochwald SN, Kukar M.

JAMA Surg. 2016 Mar;151(3):234-45. doi: 10.1001/jamasurg.2015.4068.

8.

Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.

Hoeppner J, Zirlik K, Brunner T, Bronsert P, Kulemann B, Sick O, Marjanovic G, Hopt UT, Makowiec F.

J Surg Oncol. 2014 Mar;109(3):287-93. doi: 10.1002/jso.23498. Epub 2013 Nov 26.

PMID:
24277235
9.

Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.

Franko J, Voynov G, Goldman CD.

Ann Thorac Surg. 2016 Mar;101(3):1123-30. doi: 10.1016/j.athoracsur.2015.09.044. Epub 2015 Dec 1.

PMID:
26652139
10.

Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.

Chang KJ, Reid T, Senzer N, Swisher S, Pinto H, Hanna N, Chak A, Soetikno R.

Gastrointest Endosc. 2012 Jun;75(6):1139-46.e2. doi: 10.1016/j.gie.2012.01.042. Epub 2012 Apr 18.

11.

A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.

Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA.

Eur J Cancer. 2012 Dec;48(18):3396-404. doi: 10.1016/j.ejca.2012.06.020. Epub 2012 Jul 31.

12.

Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.

Wang J, Suri JS, Allen PK, Liao Z, Komaki R, Ho L, Hofstetter WL, Lin SH.

Am J Clin Oncol. 2016 Jun;39(3):228-35. doi: 10.1097/COC.0000000000000066.

PMID:
24710122
13.

Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins.

Harvin JA, Lahat G, Correa AM, Lee J, Maru D, Ajani J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W.

J Thorac Cardiovasc Surg. 2012 Feb;143(2):412-20. doi: 10.1016/j.jtcvs.2011.10.044. Epub 2011 Dec 14.

14.

The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.

Kim GJ, Koshy M, Hanlon AL, Horiba MN, Edelman MJ, Burrows WM, Battafarano RJ, Suntharalingam M.

Am J Clin Oncol. 2016 Apr;39(2):136-41. doi: 10.1097/COC.0000000000000036.

PMID:
24487417
15.

Treatment of clinical T2N0M0 esophageal cancer.

Hardacker TJ, Ceppa D, Okereke I, Rieger KM, Jalal SI, LeBlanc JK, DeWitt JM, Kesler KA, Birdas TJ.

Ann Surg Oncol. 2014 Nov;21(12):3739-43. doi: 10.1245/s10434-014-3929-6. Epub 2014 Jul 22.

PMID:
25047477
16.

Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies.

Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Ajani JA.

J Clin Oncol. 2013 Dec 1;31(34):4306-10. doi: 10.1200/JCO.2013.51.7250. Epub 2013 Oct 21.

17.

Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation.

Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA.

Oncology. 2012;83(5):300-4. doi: 10.1159/000341353. Epub 2012 Sep 4.

18.

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.

Shao MS, Wong AT, Schwartz D, Weiner JP, Schreiber D.

Ann Thorac Surg. 2016 Jun;101(6):2148-54. doi: 10.1016/j.athoracsur.2015.12.056. Epub 2016 Mar 24.

PMID:
27016842
19.

Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.

Zanoni A, Verlato G, Giacopuzzi S, Weindelmayer J, Casella F, Pasini F, Zhao E, de Manzoni G.

Ann Surg Oncol. 2013 Jun;20(6):1993-9. doi: 10.1245/s10434-012-2822-4. Epub 2012 Dec 29.

PMID:
23274533
20.

Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.

Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.

Acta Oncol. 2012 May;51(5):636-44. doi: 10.3109/0284186X.2011.643822. Epub 2012 Jan 2.

PMID:
22208782

Supplemental Content

Support Center